The one aspect to our earnings work that might not be readily apparent to readers, is that sometimes there is little new or “value-added” to say about the weekly SP 500 earnings data, that would be worth reading. At those … Continued
There are a lot of quality “linkfests” which get distributed daily / weekly. I have to do this since it forces me to read these investors (both men and women). I want to know what this group is thinking. Gary … Continued
As we alluded to with our Earnings Update last night, the following is our second pass at 2014’s expected year-end values for the SP 500, which in turn gives us our 2014 expected returns for the SP 500 under different earnings … Continued
Per ThomsonReuters, the forward 4-quarter estimate for the SP 500 fell $0.16 last week to $117.72. The p.e ratio on the forward estimate rose to 15.3(x), which is consistent with the 2.0(x) PEG we’ve rotated around all year. The earnings … Continued
A key metric not often understood, the “forward 4-quarter growth rate” is something we calculate using the ThomsonReuter’s “Forward 4-quarter” EPS estimate for the SP 500. (The forward 4-qtr growth rate consists of the EPS estimate provided by ThomsonReuters for … Continued
In a perfect example of the navel-gazing we (I) do around SP 500 earnings data, the very detailed and elaborate Excel spreadsheet linked above, is a history of the SP 500 Earnings Revisions (by upgrades and downgrades) by week, from … Continued
Per ThomsonReuter’s “This Week in Earnings” published late Friday, 11.15.13, the “forward 4-quarter estimate” for the SP 500 slipped to $117.88 from last week’s $118.03. Substantially all of the SP 500 has now reported (per Bespoke it is widely thought … Continued
Gary Morrow is one of our favorite technicians, from our days together at the Street.com. Morrow runs a hedge fund in San Luis Obispo, Ca. and contributes to the blog “This Week on Wall Street”. Gary shot me some technical … Continued
Above / attached is a weekly chart of Pfizer (PFE) showing its slow and steady ascent from the late 2011 lows near $18 – $19 to today’s trade just above $31. Fundamentally, our ax in the pharma /biotech group is … Continued
Josh Brown, blogging for 5 years. Great stuff every day. JB covers a lot of ground, like Cramer. Those of us in the business who write, usually do it to impose a discipline on our thought process to get it … Continued